Role of the Fas/FasL pathway in combination therapy with interferon-α and fluorouracil against hepatocellular carcinoma in vitro

Journal of Hepatology

Volumn 46, Issue 1, 2007, Pages 77-88

  Nakamura, Masato ^a   Nagano, Hiroaki ^a   Sakon, Masato ^a   Yamamoto, Tameyoshi ^a   Ota, Hideo ^a   Wada, Hiroshi ^a   Damdinsuren, Bazarragchaa ^a   Noda, Takehiro ^a   Marubashi, Shigeru ^a   Miyamoto, Atsushi ^a   Takeda, Yutaka ^a   Umeshita, Koji ^a   Nakamori, Shoji ^a   Dono, Keizo ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Apoptosis; Caspase 3; Combination therapy; Fas FasL pathway; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA INTERFERON; CASPASE 3; FAS ANTIBODY; FAS LIGAND; FLICE INHIBITORY PROTEIN; FLUOROURACIL; LIPOCORTIN 5; PROTEIN BAX; PROTEIN BCL XL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TUMOR CELL LINE;

ANTIBODIES; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; CELL LINE, TUMOR; DNA, NEOPLASM; ENZYME ACTIVATION; FAS LIGAND PROTEIN; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; LIVER NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 35748985110     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.07.032     Document Type: Article

References (47)

1. Farmer D.G., Rosove M.H., Shaked A., and Busuttil R.W. Current treatment modalities for hepatocellular carcinoma. Ann Surg 219 (1994) 236-247
2. Fujii T., Takayasu K., Muramatsu Y., Moriyama N., Wakao F., Kosuge T., et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 23 (1993) 105-109
3. Ikai I., Yamaoka Y., Yamamoto Y., Ozaki N., Sakai Y., Satoh S., et al. Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy. Ann Surg 227 (1998) 433-439
4. Fan J., Wu Z.Q., Tang Z.Y., Zhou J., Qiu S.J., Ma Z.C., et al. Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. World J Gastroenterol 7 (2001) 28-32
5. Shen D.W., Lu Y.G., Chin K.V., Pastan I., and Gottesman M.M. Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression. J Cell Sci 98 (1991) 317-322
6. Doci R., Bignami P., Bozzetti F., Bonfanti G., Audisio R., Colombo M., et al. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 61 (1988) 1983-1987
7. Befeler A.S., and Di Bisceglie A.M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122 (2002) 1609-1619
8. Barnett Jr. C.C., and Curley S.A. Ablative techniques for hepatocellular carcinoma. Semin Oncol 28 (2001) 487-496
9. Llovet J.M., Sala M., Castells L., Suarez Y., Vilana R., Bianchi L., et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31 (2000) 54-58
10. Urabe T., Kaneko S., Matsushita E., Unoura M., and Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 55 (1998) 39-47
11. Patt Y.Z., Hassan M.M., Lozano R.D., Brown T.D., Vauthey J.N., Curley S.A., et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 21 (2003) 421-427
12. Sakon M., Nagano H., Dono K., Nakamori S., Umeshita K., Yamada A., et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94 (2002) 435-442
13. Ota H., Nagano H., Sakon M., Eguchi H., Kondo M., Yamamoto T., et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; Role of type1 interferon receptor expression. Br J Cancer 93 (2005) 557-564
14. Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Ota H, et al. Hepatic resection followed by IFN-α and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch, Hepatogastroenterology (in press).
15. Eguchi H., Nagano H., Yamamoto H., Miyamoto A., Kondo M., Dono K., et al. Augmentation of antitumor activity of 5-fluorouracil by interferon α is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 6 (2000) 2881-2890
16. Yamamoto T., Nagano H., Sakon M., Wada H., Eguchi H., Kondo M., et al. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against hepatocellular carcinoma. Clin Cancer Res 10 (2004) 7884-7895
17. Kondo M., Nagano H., Wada H., Damdinsuren B., Yamamoto H., Hiraoka N., et al. Combination of IFNα and 5-fluorouracil induces apoptosis through IFNα/β receptor in human hepatocellular carcinoma cells. Clin Cancer Res 11 (2005) 1277-1286
18. Chawla-Sarkar M., Lindner D.J., Liu Y.F., Williams B.R., Sen G.C., Silverman R.H., et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8 (2003) 237-249
19. van Engeland M., Ramaekers F.C., Schutte B., and Reutelingsperger C.P. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 24 (1996) 131-139
20. Metcalfe A.D., Hunter H.R., Bloor D.J., Lieberman B.A., Picton H.M., Leese H.J., et al. Expression of 11 members of the Bcl-2 family of apoptosis regulatory molecules during human preimplantation embryo development and fragmentation. Mol Reprod Dev 68 (2004) 35-50
21. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
22. Okano H., Shiraki K., Inoue H., Kawakita T., Yamanaka T., Deguchi M., et al. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 83 (2003) 1033-1043
23. Luo X., Budihardjo I., Zou H., Slaughter C., and Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94 (1998) 481-490
24. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66 (1991) 233-243
25. Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C., et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: sequence identify with the Fas antigen. J Biol Chem 267 (1992) 10709-10715
26. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
27. Kagi D., Vignaux F., Lederman B., Burki K., Depraetere V., Nagata S., et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265 (1994) 528-530
28. Berke G. The CTL's kiss of death. Cell 81 (1995) 9-12
29. Muller M., Strand S., Hug H., Heinemann E.M., Walczak H., Hofmann W.J., et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99 (1997) 403-413
30. Moers C., Warskulat U., Muschen M., Even J., Niederacher D., Josien R., et al. Regulation of CD95 (APO-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-γ and cisplatin. Int J Cancer 80 (1999) 564-572
31. Wu X.X., Mizutani Y., Kakehi Y., Yoshida O., and Ogawa O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res 60 (2000) 2912-2918
32. Mishima K., Nariai Y., and Yoshimura Y. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression. Int J Cancer 105 (2003) 593-600
33. Iwase M., Watanabe H., Kondo G., Ohashi M., and Nagumo M. Enhanced susceptibility of oral squamous cell carcinoma cell lines to Fas-mediated apoptosis by cisplatin and 5-fluorouracil. Int J Cancer 106 (2003) 619-625
34. Jiang S., Song M.J., Shin E.C., Lee M.O., Kim S.J., and Park J.H. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatology 29 (1999) 101-110
35. Yano H., Fukuda K., Haramaki M., Momosaki S., Ogasawara S., Higaki K., et al. Expression of Fas and anti-Fas-mediated apoptosis in human hepatocellular carcinoma cell lines. J Hepatol 25 (1996) 454-464
36. Wajant H. The Fas signaling pathway: more than a paradigm. Science 296 (2002) 1635-1636
37. LaCasse E.C., Baird S., Korneluk R.G., and MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17 (1998) 3247-3259
38. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
39. Baker P.K., Pettit A.R., Slupsky J.R., Chen H.J., Glenn M.A., Zuzel M., et al. Response of hairy cells to IFN-α involves induction of apoptosis through autocrine TNF-α and protection by adhesion. Blood 100 (2002) 647-653
40. Notarbartolo M., Cervello M., Dusonchet L., Cusimano A., and D'Alessandro N. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett 18 (2002) 91-101
41. Kurokawa Y., Matoba R., Nagano H., Sakon M., Takemasa I., Nakamori S., et al. Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. Clin Cancer Res 10 (2004) 6029-6038
42. Kaser A., Nagata S., and Tilg H. Interferonα augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression. Cytokine 11 (1998) 736-743
43. Damdinsuren B., Nagano H., Sakon M., Kondo M., Yamamoto T., Umeshita K., et al. Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol 10 (2003) 1184-1190
44. Higaki K., Yano H., and Kojiro M. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am J Pathol 149 (1996) 429-437
45. Ito Y., Takeda T., Umeshita K., Sakon M., Wakasa K., Matsuura N., et al. Fas antigen expression in hepatocellular carcinoma tissues. Oncol Rep 5 (1998) 41-44
46. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., et al. Lethal effect of the anti-Fas antibody in mice. Nature 364 (1993) 806-809
47. Nagata S. Apoptosis mediated by the Fas system. Prog Mol Subcell Biol 16 (1996) 87-103